RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation

Abstract Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep‐sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients. The clinical experience of BRAF‐targeted therapy in myeloma patients harboring BRAF mutation is...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, Bastien Jamet, Céline Bossard, Benoit Tessoulin, Thomas Gastinne, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Chloé Antier, Olivier Theisen, Françoise Kraeber‐Bodéré, Steven Le Gouill, Marie C. Béné, Philippe Moreau, Cyrille Touzeau
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-07-01
coleção:	eJHaem
Assuntos:	BRAF dabrafenib multiple myeloma RAS trametinib
Acesso em linha:	https://doi.org/10.1002/jha2.8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!